NCT03196986 - mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

517

Participants

Timeline

Start Date

August 15, 2017

Primary Completion Date

August 1, 2019

Study Completion Date

July 30, 2021

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

mil60

15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then maintains at 7.5mg/kg

DRUG

Bevacizumab

15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then switched to mil60 at 7.5mg/kg

Trial Locations (2)

Cancer Institute/Hospital, Chinese Academy of Medical Sciences, Beijing

Peking University Shenzhen Hospital, Shenzhen